Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Automated microscopy and Spatial Proteomics
Automated microscopy and image analysis
Discover
Related topics
Mar 22, 2024
Mission Bio’s Tapestri Tool May Hold the Key to Informing Treatment Options for Multiple Myeloma.
A 19-color single-tube Full Spectrum Flow Cytometry for the detection of Acute Myeloid Leukemia
Mar 13, 2024
This recent publication in Cytometry Part A describes the development and comprehensive workflow of a single-tube,...
18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of NETs
Mar 11, 2024
A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron...
Discover Yokogawa CellVoyager CQ1: Benchtop High-Content Analysis System
Mar 8, 2024
Unlike flow cytometers, the CellVoyager CQ1 confocal quantitative image cytometer does not require pretreatment such as...
Real-time and quantitative analysis of Macrophage Phagocytosis with RTCA eSight
Feb 23, 2024
The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance...
Visualization of Tumor-Related Blood Vessels in Small Animals by Photoacoustic 3D Imaging System
Feb 21, 2024
In Vivo Label-Free Observation of Tumor-Related Blood Vessels in Small Animals Using a Newly Designed Photoacoustic 3D...
Therapeutic effects of mesenchymal stem cells in myocardial infarction
Feb 19, 2024
Intrapericardial hydrogel injection generates high cell retention and augments therapeutic effects of mesenchymal stem...
Whole-slide biomarker quantitation in 82-patient NSCLC cohort study of acquired resistance to PD-(L)
Feb 7, 2024
Samples from 82 patients with NSCLC and matched pre- and post-ICI biopsies were subjected to genomic profiling and to...
Introducing The Cytek Orion: Reagent Cocktail Preparation System
Jan 29, 2024
Cytek is proud to announce the Cytek Orion reagent cocktail preparation system. The Cytek Orion system allows for...
Meet new Analytik Jena qTOWERiris series
Jan 19, 2024
Thanks to a very precise thermoblock made of silver and the use of a unique, super-fast and very accurate optical...
Mar 22, 2016
Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.
Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.
The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.
The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com